Skip to main content
. 2017 Jan 3;2017(1):CD000509. doi: 10.1002/14651858.CD000509.pub5

Summary of findings for the main comparison. Inhaled NO compared with control for respiratory failure in preterm infants.

Inhaled NO compared with control for respiratory failure in preterm infants
Patient or population: respiratory failure in preterm infants
 Setting: neonatal intensive care units
 Intervention: inhaled NO
 Comparison: placebo or no treatment
Outcomes Anticipated absolute effects* (95% CI) Relative effect
 (95% CI) Number of participants
 (studies) Quality of the evidence
 (GRADE) Comments
Risk with placebo or no treatment Risk with Inhaled NO
Death before discharge ‐ Studies with entry before 3 days based on oxygenation Study population RR 1.02
 (0.89 to 1.18) 1066
 (10 RCTs) ⊕⊕⊕⊕
 High  
394 per 1000 402 per 1000
 (351 to 465)
Death before discharge ‐ Studies with entry after 3 days based on BPD risk Study population RR 1.18
 (0.81 to 1.71) 1075
 (3 RCTs) ⊕⊕⊕⊕
 High  
83 per 1000 98 per 1000
 (67 to 141)
Death before discharge ‐ Studies of routine use in preterm infants on respiratory support Study population RR 0.90
 (0.74 to 1.10) 1924
 (4 RCTs) ⊕⊕⊕⊝
 Moderatea  
170 per 1000 153 per 1000
 (126 to 187)
Death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry before 3 days based on oxygenation Study population RR 0.94
 (0.87 to 1.01) 958
 (8 RCTs) ⊕⊕⊕⊕
 High  
743 per 1000 698 per 1000
 (646 to 750)
Death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry after 3 days based on BPD risk Study population RR 0.92
 (0.85 to 1.01) 1075
 (3 RCTs) ⊕⊕⊕⊕
 High  
667 per 1000 614 per 1000
 (567 to 674)
Death or bronchopulmonary dysplasia at 36 weeks ‐ Studies of routine use in preterm infants on respiratory support Study population RR 0.94
 (0.87 to 1.02) 1924
 (4 RCTs) ⊕⊕⊕⊕
 High  
548 per 1000 515 per 1000
 (477 to 559)
Intraventricular haemorrhage (grade 3 or 4) ‐ Studies with entry before 3 days based on oxygenation Study population RR 1.20
 (0.98 to 1.47) 773
 (6 RCTs) ⊕⊕⊕⊕
 High  
231 per 1000 278 per 1000
 (227 to 340)
Intraventricular haemorrhage (grade 3 or 4) ‐ Studies of routine use in preterm infants on respiratory support Study population RR 0.89
 (0.73 to 1.09) 1913
 (4 RCTs) ⊕⊕⊕⊝
 Moderateb  
127 per 1000 113 per 1000
 (93 to 139)
Neurodevelopmental disability ‐ Studies with entry before 3 days based on oxygenation Study population RR 1.05
 (0.78 to 1.40) 208
 (2 RCTs) ⊕⊕⊕⊝
 Moderatec  
455 per 1000 477 per 1000
 (355 to 636)
Neurodevelopmental disability ‐ Studies with entry after 3 days based on BPD risk Study population RR 0.90
 (0.74 to 1.09) 498
 (2 RCTs) ⊕⊕⊕⊝
 Moderatec  
480 per 1000 432 per 1000
 (355 to 523)
Neurodevelopmental disability ‐ Studies of routine use in preterm infants on respiratory support Study population RR 0.91
 (0.74 to 1.13) 1223
 (3 RCTs) ⊕⊕⊕⊕
 High  
195 per 1000 178 per 1000
 (144 to 220)
*The risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and relative effect of the intervention (and its 95% CI).
 
 CI: confidence interval; OR: odds ratio; RR: risk ratio.
GRADE Working Group grades of evidence.High quality: We are very confident that the true effect lies close to that of the estimate of effect.
 Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.
 Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.
 Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

aHighly variable risk ratio in individual trials (I2 = 50%).

bHighly variable risk ratio in individual trials (I2 = 33%).

cBased on 2 studies, wide confidence intervals.